Wednesday, 22 March 2017

EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme

Latest news --

1 comment:

  1. A brief description of this therapy here:

    First in human case study here:

    An interesting thing about doxorubicin is that it's a bona fide inducer of immunogenic cell death, which means it kills cells in such a way that the dying cell releases danger signals that arouse an immune response.